Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7910033rdf:typepubmed:Citationlld:pubmed
pubmed-article:7910033lifeskim:mentionsumls-concept:C0052059lld:lifeskim
pubmed-article:7910033lifeskim:mentionsumls-concept:C0542341lld:lifeskim
pubmed-article:7910033lifeskim:mentionsumls-concept:C1514562lld:lifeskim
pubmed-article:7910033lifeskim:mentionsumls-concept:C1883221lld:lifeskim
pubmed-article:7910033lifeskim:mentionsumls-concept:C1883204lld:lifeskim
pubmed-article:7910033lifeskim:mentionsumls-concept:C1880389lld:lifeskim
pubmed-article:7910033pubmed:issue18lld:pubmed
pubmed-article:7910033pubmed:dateCreated1994-6-10lld:pubmed
pubmed-article:7910033pubmed:abstractTextSecretory leukoprotease inhibitor (SLPI) comprises two homologous domains: the C-terminal domain contains the reactive site, while the function of the N-terminal domain remains unknown. In order to elucidate the function of the N-terminal domain, we studied the kinetics of reactions of human leukocyte elastase with two recombinant forms of SLPI: the full-length inhibitor and the C-terminal domain alone. The reactions of elastase with the full-length inhibitor and the C-terminal domain share the same association rate constant, 2 x 10(6) M-1 s-1, but the complex formed with the C-terminal domain is less stable, with a dissociation rate constant of 8 x 10(-4) s-1, 5 times higher than that of the complex with the full-length inhibitor. The binding of the full-length inhibitor to elastase is greatly accelerated by polyanions. In the presence of submicromolar concentrations (1 microgram/mL) of heparin, the association rate constant is increased by more than 1 order of magnitude. The binding of the C-terminal domain alone to elastase shows much lower sensitivity to heparin; in the presence of 5 microM (25 micrograms/mL) heparin, association of the C-terminal domain with elastase reaches a maximum rate of 7 x 10(6) M-1 s-1, about 3 times higher than the rate in the absence of heparin. Similar differential effects of heparin have been observed on the reactions of alpha-chymotrypsin with the two recombinant forms of SLPI.2=lld:pubmed
pubmed-article:7910033pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7910033pubmed:languageenglld:pubmed
pubmed-article:7910033pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7910033pubmed:citationSubsetIMlld:pubmed
pubmed-article:7910033pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7910033pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7910033pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7910033pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7910033pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7910033pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7910033pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7910033pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7910033pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7910033pubmed:statusMEDLINElld:pubmed
pubmed-article:7910033pubmed:monthMaylld:pubmed
pubmed-article:7910033pubmed:issn0006-2960lld:pubmed
pubmed-article:7910033pubmed:authorpubmed-author:SimonS RSRlld:pubmed
pubmed-article:7910033pubmed:authorpubmed-author:KemmeMMlld:pubmed
pubmed-article:7910033pubmed:authorpubmed-author:YingQ LQLlld:pubmed
pubmed-article:7910033pubmed:issnTypePrintlld:pubmed
pubmed-article:7910033pubmed:day10lld:pubmed
pubmed-article:7910033pubmed:volume33lld:pubmed
pubmed-article:7910033pubmed:ownerNLMlld:pubmed
pubmed-article:7910033pubmed:authorsCompleteYlld:pubmed
pubmed-article:7910033pubmed:pagination5445-50lld:pubmed
pubmed-article:7910033pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:7910033pubmed:meshHeadingpubmed-meshheading:7910033-...lld:pubmed
pubmed-article:7910033pubmed:meshHeadingpubmed-meshheading:7910033-...lld:pubmed
pubmed-article:7910033pubmed:meshHeadingpubmed-meshheading:7910033-...lld:pubmed
pubmed-article:7910033pubmed:meshHeadingpubmed-meshheading:7910033-...lld:pubmed
pubmed-article:7910033pubmed:meshHeadingpubmed-meshheading:7910033-...lld:pubmed
pubmed-article:7910033pubmed:meshHeadingpubmed-meshheading:7910033-...lld:pubmed
pubmed-article:7910033pubmed:meshHeadingpubmed-meshheading:7910033-...lld:pubmed
pubmed-article:7910033pubmed:meshHeadingpubmed-meshheading:7910033-...lld:pubmed
pubmed-article:7910033pubmed:meshHeadingpubmed-meshheading:7910033-...lld:pubmed
pubmed-article:7910033pubmed:meshHeadingpubmed-meshheading:7910033-...lld:pubmed
pubmed-article:7910033pubmed:meshHeadingpubmed-meshheading:7910033-...lld:pubmed
pubmed-article:7910033pubmed:meshHeadingpubmed-meshheading:7910033-...lld:pubmed
pubmed-article:7910033pubmed:meshHeadingpubmed-meshheading:7910033-...lld:pubmed
pubmed-article:7910033pubmed:meshHeadingpubmed-meshheading:7910033-...lld:pubmed
pubmed-article:7910033pubmed:year1994lld:pubmed
pubmed-article:7910033pubmed:articleTitleFunctions of the N-terminal domain of secretory leukoprotease inhibitor.lld:pubmed
pubmed-article:7910033pubmed:affiliationDepartment of Pathology, State University of New York at Stony Brook 11794.lld:pubmed
pubmed-article:7910033pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7910033pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:7910033pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7910033lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7910033lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7910033lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7910033lld:pubmed